Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: JEB who wrote (152)	3/11/2002 12:12:05 AM
From: Jibacoa	Read Replies (1) \| Respond to of 544

AGEN Seems to have recently found bottom at 11.<g> The insiders hold close to 50% and had been doing some buying lately. The institutions hold about 21% (42% of float) and also reportedly have been buying lately. They have a wide range of products for treatment of cancers, infectious diseases, autoimmune and degenerative disorders. One of their most advanced products is Oncophage, a personalized cancer vaccine in Phase III trials and on the FDA's Fast Track development program. They also have two liposomal products in Phase II development: Aroplatin and ATRA-IV (This last one is a form of vitamin A used to treat lymphoma) They also have AG-702, which is in Phase I testing for treatment of genital herpes. They still lost $0.48 in the last Q, albeit this was at a somewhat slower pace than previously.<g>They reportedly have about $2.47 cash/share. I like the chart and bought some on the buy signal earlier this week. siliconinvestor.com siliconinvestor.com siliconinvestor.com Bernard